Comparative Pharmacology
Head-to-head clinical analysis: ALIQOPA versus COPIKTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALIQOPA versus COPIKTRA.
ALIQOPA vs COPIKTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.
Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.
60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
25 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life of approximately 39 hours in patients with hematologic malignancies; supports twice-daily dosing.
Terminal elimination half-life is approximately 7–10 hours in patients with relapsed or refractory CLL/SLL. Steady-state is achieved within 3–5 days of twice-daily dosing.
Primarily fecal (88%) and renal (8%) as unchanged drug and metabolites; biliary excretion contributes significantly.
Primarily via fecal excretion (approximately 70% of total dose) as unchanged drug and metabolites, with renal excretion accounting for <15% of the dose.
Category C
Category C
PI3K Inhibitor Antineoplastic
PI3K Inhibitor Antineoplastic